• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2014-2016 年美国肌萎缩侧索硬化症发病率。

Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016.

机构信息

Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, Office of Innovation and Analytics, National ALS Registry, GA, USA and.

Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, Office of Community Health and Hazard Assessment, Atlanta, GA, USA.

出版信息

Amyotroph Lateral Scler Frontotemporal Degener. 2022 Aug;23(5-6):378-382. doi: 10.1080/21678421.2021.2023190. Epub 2022 Jan 13.

DOI:10.1080/21678421.2021.2023190
PMID:35023792
Abstract

To estimate the incidence of amyotrophic lateral sclerosis (ALS) in the United States for calendar years 2014-2016 using data from the National ALS Registry (Registry). The Registry collects data on ALS patients in the United States to better describe the epidemiology of ALS, examine risk factors such as environmental and occupational exposures, and characterize the demographics of those living with the disease. To identify adult incident cases of ALS, the Registry compiles data from three national administrative databases (maintained by the Centers for Medicare and Medicaid Services, the Veterans Health Administration, and the Veterans Benefits Administration). For cases that are not included in these databases, the Registry includes data collected from patients who voluntarily enroll a secure web portal. The Registry identified 5695 ALS cases in 2014; 6045 cases in 2015; and 4861 cases in 2016 for age-adjusted incidence rates of 1.7 (2014), 1.5 (2015), and 1.5 (2016) per 100,000 U.S. population, respectively. ALS was more common among whites, males, and persons aged 60-79 years. This is the first time administrative and self-reported databases have been used to describe the incidence of ALS for the United States resulting in a better estimate of disease demographics.

摘要

利用国家肌萎缩侧索硬化症登记处(登记处)的数据,估算 2014-2016 年美国肌萎缩侧索硬化症(ALS)的发病率。该登记处收集美国 ALS 患者的数据,以更好地描述 ALS 的流行病学,检查环境和职业暴露等风险因素,并描述患有该病的人群特征。为了确定成人新发 ALS 病例,登记处从三个国家管理数据库(由医疗保险和医疗补助服务中心、退伍军人健康管理局和退伍军人福利管理局维护)中编译数据。对于未包含在这些数据库中的病例,登记处包括从自愿注册安全门户网站的患者中收集的数据。登记处于 2014 年确定了 5695 例 ALS 病例;2015 年为 6045 例;2016 年为 4861 例,年龄调整后的发病率分别为每 10 万美国人口 1.7(2014 年)、1.5(2015 年)和 1.5(2016 年)。ALS 在白人、男性和 60-79 岁人群中更为常见。这是首次利用管理和自我报告数据库来描述美国 ALS 的发病率,从而更好地估计疾病人群特征。

相似文献

1
Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016.2014-2016 年美国肌萎缩侧索硬化症发病率。
Amyotroph Lateral Scler Frontotemporal Degener. 2022 Aug;23(5-6):378-382. doi: 10.1080/21678421.2021.2023190. Epub 2022 Jan 13.
2
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013.肌萎缩侧索硬化症的患病率 - 美国,2012-2013 年。
MMWR Surveill Summ. 2016 Aug 5;65(8):1-12. doi: 10.15585/mmwr.ss6508a1.
3
Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016.2016年美国肌萎缩侧索硬化症(ALS)的患病率
Amyotroph Lateral Scler Frontotemporal Degener. 2022 May;23(3-4):220-225. doi: 10.1080/21678421.2021.1949021. Epub 2021 Aug 23.
4
Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011.2010 - 2011年美国肌萎缩侧索硬化症的患病率
MMWR Suppl. 2014 Jul 25;63(7):1-14.
5
Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017.使用既定和新颖方法在美国评估肌萎缩性侧索硬化症的患病率,2017 年。
Amyotroph Lateral Scler Frontotemporal Degener. 2023 Feb;24(1-2):108-116. doi: 10.1080/21678421.2022.2059380. Epub 2022 Apr 15.
6
Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data.国家肌萎缩侧索硬化症(ALS)登记处危险因素调查数据的初步结果。
PLoS One. 2016 Apr 28;11(4):e0153683. doi: 10.1371/journal.pone.0153683. eCollection 2016.
7
Prevalence of amyotrophic lateral sclerosis in the United States, 2018.2018年美国肌萎缩侧索硬化症的患病率
Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug 21:1-7. doi: 10.1080/21678421.2023.2245858.
8
Evaluation of the Completeness of ALS Case Ascertainment in the US National ALS Registry: Application of the Capture-Recapture Method.应用捕获-再捕获法评价美国国家肌萎缩侧索硬化症注册中心肌萎缩侧索硬化症病例确定的完整性
Neuroepidemiology. 2022;56(2):104-114. doi: 10.1159/000521591. Epub 2021 Dec 20.
9
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015.肌萎缩侧索硬化症的流行情况-美国,2015 年。
MMWR Morb Mortal Wkly Rep. 2018 Nov 23;67(46):1285-1289. doi: 10.15585/mmwr.mm6746a1.
10
Feasibility of creating a National ALS Registry using administrative data in the United States.利用美国行政数据创建全国肌萎缩侧索硬化症登记处的可行性。
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):433-9. doi: 10.3109/21678421.2014.887119. Epub 2014 Mar 6.

引用本文的文献

1
Racial and ethnic disparities in ALS: a longitudinal electronic health records study.肌萎缩侧索硬化症中的种族和民族差异:一项纵向电子健康记录研究。
Ther Adv Neurol Disord. 2025 Sep 1;18:17562864251365001. doi: 10.1177/17562864251365001. eCollection 2025.
2
Metal-Induced Genotoxic Events: Possible Distinction Between Sporadic and Familial ALS.金属诱导的基因毒性事件:散发性和家族性肌萎缩侧索硬化症之间的可能区别
Toxics. 2025 Jun 12;13(6):493. doi: 10.3390/toxics13060493.
3
Pathological Aging of Patients With Amyotrophic Lateral Sclerosis: A Preliminary Longitudinal Study.
肌萎缩侧索硬化症患者的病理性衰老:一项初步纵向研究。
Brain Behav. 2025 May;15(5):e70484. doi: 10.1002/brb3.70484.
4
ALS: A Silent Slayer of Motor Neurons. Traditional Chinese Herbal Medicine as an Effective Therapy.肌萎缩侧索硬化症:运动神经元的无声杀手。传统中药作为一种有效疗法。
Curr Pharm Des. 2025;31(17):1328-1346. doi: 10.2174/0113816128329141241205063352.
5
Comparison of Demographics: National Amyotrophic Lateral Sclerosis Registry and Clinical Trials Data.人口统计学比较:国家肌萎缩侧索硬化症注册库与临床试验数据
J Racial Ethn Health Disparities. 2024 Jul 8. doi: 10.1007/s40615-024-02047-4.
6
Brain-body mechanisms contribute to sexual dimorphism in amyotrophic lateral sclerosis.大脑-身体机制导致肌萎缩侧索硬化症的性别二态性。
Nat Rev Neurol. 2024 Aug;20(8):475-494. doi: 10.1038/s41582-024-00991-7. Epub 2024 Jul 4.
7
The role of statins in amyotrophic lateral sclerosis: protective or not?他汀类药物在肌萎缩侧索硬化症中的作用:是否具有保护作用?
Front Neurosci. 2024 Jun 5;18:1422912. doi: 10.3389/fnins.2024.1422912. eCollection 2024.
8
Chronological and Biological Aging in Amyotrophic Lateral Sclerosis and the Potential of Senolytic Therapies.肌萎缩侧索硬化症中的时间和生物学衰老及衰老细胞清除疗法的潜力。
Cells. 2024 May 28;13(11):928. doi: 10.3390/cells13110928.
9
Enhancing Clinical Infrastructure for the Delivery of Intrathecal and Genetic Therapies: A Qalsody (Tofersen) Model for Patients With -ALS.加强鞘内注射和基因治疗的临床基础设施:肌萎缩侧索硬化症患者的Qalsody(托弗生)模式。
Neurol Clin Pract. 2024 Aug;14(4):e200303. doi: 10.1212/CPJ.0000000000200303. Epub 2024 May 16.
10
What do you think caused your ALS? An analysis of the CDC national amyotrophic lateral sclerosis patient registry qualitative risk factor data using artificial intelligence and qualitative methodology.你认为是什么导致了你的肌萎缩侧索硬化症?利用人工智能和定性方法对疾病预防控制中心国家肌萎缩侧索硬化症患者登记处定性危险因素数据的分析。
Amyotroph Lateral Scler Frontotemporal Degener. 2024 Aug;25(5-6):615-624. doi: 10.1080/21678421.2024.2349920. Epub 2024 May 8.